NasdaqGS:SRPTBiotechs
Sarepta Therapeutics (SRPT) Q4 Loss Deepens And Tests Bullish Profitability Narrative
Sarepta Therapeutics (SRPT) closed out FY 2025 with Q4 revenue of US$442.9 million and a basic EPS loss of US$3.93, alongside a full year trailing net loss of US$713.4 million on US$2.2 billion of revenue. Over the last six quarters in the data, revenue has ranged from US$399.4 million to US$744.9 million per quarter. Basic EPS has swung between a profit of US$2.01 and a loss of US$4.60, highlighting sharp shifts in margins that keep profitability firmly in focus for investors.
See our full...